- Home
- NVNI vs BCAB Comparison
NVNI vs BCAB Comparison
Compare NVNI & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NVNI | BCAB |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | Brazil | United States |
| Employees | N/A | 61 |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4M | 12.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NVNI | BCAB |
|---|---|---|
| Price | $1.32 | $0.19 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 89.2K | ★ 1.9M |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.19 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | $6.67 | N/A |
| Revenue Next Year | $26.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $0.13 |
| 52 Week High | $4.94 | $1.43 |
Technical Indicators
Market Signals| Indicator | NVNI | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 37.16 | 42.23 |
| Support Level | $1.10 | $0.13 |
| Resistance Level | $1.64 | $0.27 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 35.99 | 42.96 |
Price Performance
Historical ComparisonAbout NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.